A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. - Wikidata - awgldk - TriplyDB

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q34537737

about

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials.Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.Systemic safety of anti-VEGF drugs: a commentary.Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration.Anti-vascular endothelial growth factor therapy for diabetic macular edema Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation.Age-related macular degeneration: anti-vascular endothelial growth factor treatment.Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.Relationship between macular thickness measurement and signal strength using Stratus optical coherence tomography.Beyond VEGF-The Weisenfeld Lecture.An update on the pharmacotherapy of neovascular age-related macular degeneration.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Current choice of treatments for neovascular AMD.Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis."What should I inject next?" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD.Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.

P2860

Q24193614-00BEAA99-2068-4360-BF52-497401AE9872 Q24194251-43B3F28E-0DED-4309-ABBC-70E78D656F91 Q26472033-267889F2-9546-41D3-8AA4-9E7E019D780E Q26767095-0A93312A-DD93-4E6C-B9EF-E1EA8628A049 Q26785646-0DFB1B69-74FC-41A0-B3E5-6BA8CF23C64F Q26799492-87A0CCD1-5565-4BBF-A42F-35D932369109 Q26824335-17CFE11F-A7E7-4CE8-B1FD-8E0B49C90F95 Q26852289-E9D3F7F4-EC3B-4A6C-B22B-D970081AEF68 Q26995216-436A2043-CF2F-4312-89BF-B32F86FB1179 Q28049700-DF5289EF-E54D-487F-A59C-781509C8A021 Q30490738-625EC64B-E966-4421-AFC8-C7CB2FEA9225 Q31155420-2A6A2E8F-0AF8-4371-A4D7-C0FE9A1071F8 Q33830753-0CBC9850-B59F-42CC-A5F1-7DE945DFFBD0 Q34170457-EAB94513-14FE-4F2E-8076-264ABF2670CF Q34271021-D6408D5A-B343-4895-94EC-582C4C1668AC Q34444212-8BAE8B23-259C-460C-8D2B-A0A76DCF0419 Q34452811-30156D82-ABA6-4FBD-B930-2B0C2FD887EE Q34554380-BD025C30-3668-44E6-8511-8F32CD9D8294 Q34608306-1DC10F27-FBEE-495F-A00F-F4938ACA270F Q34645786-6D95CB44-4F0D-449B-87B7-61CF47A28ACF Q34961356-A39495EE-C339-4950-A495-C33612C14D5A Q35064343-54B6EF14-343D-4560-8772-D8FA89FE1C3E Q35075402-DC4E0FDC-3A48-4243-9784-FAC3859EC71E Q35135745-045439A2-09BA-47A0-AD04-C196D1403076 Q35436686-840515D6-9E67-4371-B832-32ECBD214FFC Q35933831-FD6DB03C-3483-4141-9DB5-180FBECE733C Q35996271-B89746CF-C675-4B60-ABBF-E642B4053367 Q36023946-7D5CE309-1A0B-4A6B-8A1D-069774B638A2 Q36414769-FB1CE594-8911-43A8-89F3-C4EB6009D5D0 Q36757415-A683A5AF-D18A-4146-A4E0-FE9D395DBEA8 Q36788529-C96C5AB3-267F-46C8-92A3-9DA6DF5A1BDE Q37183169-63D171A9-6627-46F3-8E36-A1466DE330C0 Q37420733-510E0ED1-6EE2-46DB-9725-0AC58E4FCC6D Q37558259-65559405-AE9C-4CA1-8BFE-3FF4987871E5 Q38096462-F541695F-A9CC-44BF-8A29-4FE498454204 Q38210239-DEBD23DD-12F0-4517-A3B2-68510E2C5AA6 Q38285319-B6201B78-4129-410D-8771-0E7E9F4521AD Q38598693-6B8B11EE-FD89-445D-9680-37D85AEFBD98 Q38602658-E5CD13AA-0933-4115-BEB5-953275056743 Q38764072-5F04E711-B1D1-46FD-B9C9-037E54FEEC6E

P2860

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q34537737

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A randomised double-masked tri ...... -related macular degeneration.

@ast

A randomised double-masked tri ...... -related macular degeneration.

@en

A randomised double-masked tri ...... -related macular degeneration.

@nl

type

label

A randomised double-masked tri ...... -related macular degeneration.

@ast

A randomised double-masked tri ...... -related macular degeneration.

@en

A randomised double-masked tri ...... -related macular degeneration.

@nl

prefLabel

A randomised double-masked tri ...... -related macular degeneration.

@ast

A randomised double-masked tri ...... -related macular degeneration.

@en

A randomised double-masked tri ...... -related macular degeneration.

@nl

P1433

Q34537737-BE414CA6-9E6F-4114-8B02-826F2AAEE470

P1476

Q34537737-96178A89-6A4A-4068-937C-672EE5D5E6E0

P2093

Q34537737-027EC715-2B52-4EF6-834B-7DFD11D89523

Q34537737-30A587D9-3133-4A1B-B163-DCD16E918874

Q34537737-443B71F4-9977-47CC-88D5-653661FF73BB

Q34537737-59C61947-626C-47E9-B897-C7F385DC28A0

Q34537737-5B360705-C5C6-4D0A-A0F1-86546A694F6F

Q34537737-5C4BEC03-5258-48FA-99B3-773E4AD672D7

Q34537737-5F08F89B-D84B-454A-A799-63BA61CD92DD

Q34537737-6016C813-1896-4706-8BB3-AAD6CDD66A70

Q34537737-AA34D87F-26C9-42C6-ADDA-370DEC799A74

P304

Q34537737-F1B13697-A924-4B68-8267-50420C65D031

P31

Q34537737-8AB16D3A-9900-478F-800E-7991954F7641

P356

Q34537737-A8492EF9-15FD-4620-876E-92E4E2177A97

P407

Q34537737-F058A1EE-C08C-48A7-9571-286FA94D9C63

P433

Q34537737-D4046261-AB57-43A9-9FD2-B72EB4D529CA

P478

Q34537737-8515BE77-9C2F-43B0-8F98-3288368BA965

P50

Q34537737-63A0ACDC-8EF7-48AB-91B5-A8228202D65A

Q34537737-7883F807-5E71-4D4A-B97B-1A2BB1F611D0

P577

Q34537737-3E41D134-CBDD-4F08-9682-75206AFA8D29

P698

Q34537737-C02BBF5E-7441-4BD6-A391-77D85D5A5E2C

P921

Q34537737-5AA1F31C-D92B-49DA-B4F1-5BA9F9337DEF

Q34537737-E0EADD56-DFEC-495A-8A35-BE872CCC59BC

P356

BJOPHTHALMOL-2012-302391

P1433

British Journal of Ophthalmology

P1476

A randomised double-masked tri ...... -related macular degeneration.

@en

P2093

Agnes Boltz

http://www.w3.org/2001/XMLSchema#string

Anton Haas

http://www.w3.org/2001/XMLSchema#string

Ilse Krebs

http://www.w3.org/2001/XMLSchema#string

MANTA Research Group

http://www.w3.org/2001/XMLSchema#string

Siamak Ansari-Shahrezaei

http://www.w3.org/2001/XMLSchema#string

Stefan Egger

http://www.w3.org/2001/XMLSchema#string

Susanne Binder

http://www.w3.org/2001/XMLSchema#string

Ulrich Schönherr

http://www.w3.org/2001/XMLSchema#string

Veronika Vécsei-Marlovits

http://www.w3.org/2001/XMLSchema#string

P304

266-271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJOPHTHALMOL-2012-302391

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Leopold Schmetterer

P577

2013-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23292928

http://www.w3.org/2001/XMLSchema#string

P921